Literature DB >> 27799205

In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli.

M L Monogue1, D P Nicolau2,3.   

Abstract

Recent findings have identified Escherichia coli strains that are pan-β-lactam susceptible (PBL-S) but piperacillin-tazobactam resistant (TZP-R) in vitro We assessed the in vivo significance of this resistance profile in a neutropenic murine pneumonia model using humanized exposures of TZP with 18 clinical E. coli isolates, 8 TZP-S/PBL-S and 10 genotypically confirmed TZP-R/PBL-S. Despite phenotypically and genotypically defined resistance, TZP displayed efficacy against these isolates. Additional studies are required to define the clinical implications of these TZP-R/PBL-S strains.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27799205      PMCID： PMC5119043          DOI： 10.1128/AAC.01208-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.

Authors:  Ken Coleman; Premavathy Levasseur; Anne-Marie Girard; Monica Borgonovi; Christine Miossec; Henri Merdjan; George Drusano; David Shlaes; Wright W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.

Authors:  Catharine C Bulik; Pamela R Tessier; Rebecca A Keel; Christina A Sutherland; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

3.  Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.

Authors:  Catharine C Bulik; Henry Christensen; Peng Li; Christina A Sutherland; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

4.  Impact of blaNDM-1 on fitness and pathogenicity of Escherichia coli and Klebsiella pneumoniae.

Authors:  Stephan Göttig; Sara Riedel-Christ; Ahmad Saleh; Volkhard A J Kempf; Axel Hamprecht
Journal:  Int J Antimicrob Agents       Date:  2016-04-26       Impact factor: 5.283

Review 5.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

6.  Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.

Authors:  Christina A Sutherland; David P Nicolau
Journal:  Clin Ther       Date:  2015-06-15       Impact factor: 3.393

7.  In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae.

Authors:  Catharine C Bulik; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

8.  Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.

Authors:  Jared L Crandon; Virna J Schuck; Mary Anne Banevicius; Marie-Eve Beaudoin; Wright W Nichols; M Angela Tanudra; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

9.  The Pandemic H30 Subclone of Escherichia coli Sequence Type 131 Is Associated With Persistent Infections and Adverse Outcomes Independent From Its Multidrug Resistance and Associations With Compromised Hosts.

Authors:  James R Johnson; Paul Thuras; Brian D Johnston; Scott J Weissman; Ajit P Limaye; Kim Riddell; Delia Scholes; Veronika Tchesnokova; Evgeni Sokurenko
Journal:  Clin Infect Dis       Date:  2016-03-29       Impact factor: 9.079

10.  Inhibition of the renal excretion of tazobactam by piperacillin.

Authors:  M Komuro; T Maeda; H Kakuo; H Matsushita; J Shimada
Journal:  J Antimicrob Chemother       Date:  1994-10       Impact factor: 5.790
View more
  5 in total

1.  Assessment of the In Vivo Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model.

Authors:  Sean M Stainton; Kamilia Abdelraouf; Luke Utley; Michael J Pucci; Troy Lister; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

2.  In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Klebsiella pneumoniae Strains.

Authors:  S M Stainton; M L Monogue; D P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

3.  Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model.

Authors:  Lindsay M Avery; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

4.  Epidemiology of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible.

Authors:  Thomas M Baker; Wesley Rogers; Kalyan D Chavda; Lars F Westblade; Stephen G Jenkins; David P Nicolau; Barry N Kreiswirth; David P Calfee; Michael J Satlin
Journal:  Open Forum Infect Dis       Date:  2018-11-19       Impact factor: 3.835

5.  Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli.

Authors:  Lisa M Schechter; David P Creely; Cherilyn D Garner; Dee Shortridge; Hoan Nguyen; Lei Chen; Blake M Hanson; Erica Sodergren; George M Weinstock; W Michael Dunne; Alex van Belkum; Shana R Leopold
Journal:  MBio       Date:  2018-04-24       Impact factor: 7.867
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.